Uncategorized

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Lexicon Pharmaceuticals, Inc. announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® use in heart failure and major adverse cardiovascular events related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events.

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data Read More »

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

Ascletis Pharma Inc. announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 for functional cure of chronic hepatitis B, and abstract poster presentation of Phase I study results of ASC41 for treatment of non-alcoholic steatohepatitis at The Liver Meeting® 2023 of the American Association for the Study of Liver

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB Read More »

AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions

Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a Phase 1 trial investigating AB-1002 for the treatment of patients with congestive heart failure at this year’s American Heart Association Scientific Sessions, which are being held in Philadelphia, U.S., from November 11

AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions Read More »

Scroll to Top